Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is -82.46% lower on its value in year-to-date trading and has touched a low of $0.10 and a high of $0.94 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRBP stock was last observed hovering at around $0.11 in the last trading session, with the day’s loss setting it 0.0% off its average median price target of $3.00 for the next 12 months. It is also 96.33% off the consensus price target high of $3.00 offered by 2 analysts, but current levels are 96.33% higher than the price target low of $3.00 for the same period.
Currently trading at $0.11, the stock is -14.99% and -26.45% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.46 million and changing -3.66% at the moment leaves the stock -60.75% off its SMA200. CRBP registered -87.79% loss for a year compared to 6-month loss of -65.25%.
The stock witnessed a -7.77% gain in the last 1 month and extending the period to 3 months gives it a -49.77%, and is -19.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.38% over the week and 8.66% over the month.
Corbus Pharmaceuticals Holdings Inc. (CRBP) has around 41 employees, a market worth around $14.92M and $0.00M in sales. Distance from 52-week low is 8.00% and -88.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.20%).
Corbus Pharmaceuticals Holdings Inc. (CRBP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Corbus Pharmaceuticals Holdings Inc. (CRBP) is a “Overweight”. 2 analysts offering their recommendations for the stock have an average rating of 2.50, where 1 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Corbus Pharmaceuticals Holdings Inc. is expected to release its quarterly report on 03/13/2023.The EPS is expected to grow by 73.90% this year.
Corbus Pharmaceuticals Holdings Inc. (CRBP) Top Institutional Holders
The shares outstanding are 125.27M, and float is at 124.68M with Short Float at 3.82%.
Corbus Pharmaceuticals Holdings Inc. (CRBP) Insider Activity
A total of 3 insider transactions have happened at Corbus Pharmaceuticals Holdings Inc. (CRBP) in the last six months, with sales accounting for 0 and purchases happening 3 times. The most recent transaction is an insider purchase by Millian Craig Stuart,the company’sChief Operating Officer. SEC filings show that Millian Craig Stuart bought 5,000 shares of the company’s common stock on Aug 10 at a price of $0.25 per share for a total of $1272.0. Following the purchase, the insider now owns 27000.0 shares.
Corbus Pharmaceuticals Holdings Inc. disclosed in a document filed with the SEC on Aug 10 that Moran Sean F. (Chief Financial Officer) bought a total of 20,000 shares of the company’s common stock. The trade occurred on Aug 10 and was made at $0.26 per share for $5198.0. Following the transaction, the insider now directly holds 0.2 million shares of the CRBP stock.
Still, SEC filings show that on Aug 10, Cohen Yuval (Chief Executive Officer) acquired 3,800 shares at an average price of $0.26 for $1003.0. The insider now directly holds 98,230 shares of Corbus Pharmaceuticals Holdings Inc. (CRBP).
Corbus Pharmaceuticals Holdings Inc. (CRBP): Who are the competitors?
The company’s main competitors (and peers) include Vanda Pharmaceuticals Inc. (VNDA) that is trading -37.67% down over the past 12 months and Fortress Biotech Inc. (FBIO) that is -74.66% lower over the same period. Viking Therapeutics Inc. (VKTX) is -26.18% down on the 1-year trading charts.